2025-06-09-Jefferies-买方最常阅读的生命科学工具和诊断报告_9页_135kb

Equity Research Summary: Life Science Tools & Diagnostics

Most-Read Industry Notes (May)

• Refreshing Math on US Biopharma Investment Commitments ($200B+)
• U.S. Academic Research Vibe Assessment
• Analysis Following Trade Deal & Medicaid Budget Cuts
• Introduction to MRD Market Model
• Chart on Biopharma Pull-Forward Debate (1Q Results Context)
• Roche Diagnostics Day '25 Insights (NGS, MDx, LC/MS)
• Eli Lilly's $6B Houston Expansion Plans
• Video: Battle for Lab Budgets (Purchasing Head Discussion)
• US Academic & Government Grant Analysis
• April NIH Outlays (-8% YoY)

Most-Read Company Notes (May)

• WGS: Upgrade to Buy (Valuation, Margins, COGS Leverage)
• MTD: Hold Rating (Valuation Floor, Tariff Impact)
• EXAS: Outperform to Hold (Consolidated 1Q Performance)
• QGEN: Buy Rating Maintained (Dx Trends, Neutral 2H View)
• WAT: Upgrade to Buy (Tariff Offset, 2025 Outlook)

Analyst Certification & Contact

• Tycho Peterson, Matthew Stanton, Jack Melick, Priya Patel, Noah Kava, Lauren Timmins (Equity Analysts/Associates)

Analyst Notes (Rating Summary)

1. EXAS (Exact Sciences):

   • Recommendations/Price Target: Buy ($80) based on DCF. Risks: Pipeline execution, commercial leverage, liquid biopsy competition.

2. GeneDx:

   • Recommendations/Price Target: Buy ($80) based on DCF. EV/Revenues: 6x (2025E). Risks: Competition, reimbursement pressure, dilutive financing. Upside: Higher margins.

3. Mettler-Toledo:

   • Recommendations/Price Target: Hold ($1,110). Downside: Weak industrial demand, lab shutdowns. Upside: China recovery, service growth, buybacks.

4. Qiagen:

   • Recommendations/Price Target: Buy ($54). Risks: QuantiFERON loss, A&G/biopharma weakness, NPI/NexQuant delays, dPCR slowdown.

5. Waters:

   • Recommendations/Price Target: Hold ($435). Risks: China affordability, biopharma slowdown, dilutive M&A. Upside: Service growth, product mix gains.

Other Notable Sections:

• Company Specific Disclosures: Conflicts of interest (e.g., Jefferies makes markets in GeneDx securities).
• Ratings Explanation: Buy/Hold/Underperform definitions vary based on price and volatility.
• Valuation Methodology: DCF, EBITDA, EV/EBITDA, EPS, P/E etc.
• Jefferies Franchise Picks: Buy-rated stocks based on analyst conviction and investment themes.
• Price Target & Rating History: Visual charts for each company, showing recent price targets and rating changes ($WAT to Buy, $QGEN to Hold etc.).

Analyst & Equity Research Overview

• Tycho Peterson, Matthew Stanton, and others certify that recommendations solely reflect their views and are independent of performance-based incentives.